Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News out on Ludg looking good.
News out today.
SPARKS, NV / ACCESSWIRE / March 7, 2023 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), The Genomics Language Company™ is pleased to announce an agreement with Drs. Kim Farahay and Jeff Lee to provide them with the Company's newly developed program for use of the mRNA Inflammatory Index™ in Ketamine treatment of patients with Treatment Resistant Depression. Drs. Farahay and Lee are finalizing plans to open a Ketamine clinic in southeastern Ohio in 2023.
"Major depressive disorder is one of the leading causes of morbidity and all-cause mortality (including suicide) worldwide," said Dr. Marvin S. Hausman, MD, Chief Medical Officer of Ludwig Enterprises, and creator of the mRNA Inflammatory Index™. "Our mRNA Inflammatory Index could become a reliable and reproducible biomarker guide to patient treatment selection, evaluation of ketamine dosage used and therapeutic response."
Ketamine is a pharmaceutical discovered over 60 years ago originally approved by the FDA as an anesthetic and analgesic. It was first used psychotherapeutically and for post operative pain in 1974. It was added to the WHO's list of Essential Medicines in 1985. Studies in the early 2000s found Ketamine to be effective in fighting depression resistant to other treatments.
"The ketamine clinic industry is growing rapidly," said Dr. Jeff Lee, the clinic's co-founder. "Our partnership with Ludwig - The Genomics Language Company™ will provide artificial intelligence (AI) to track mRNA inflammatory markers in patients with treatment resistant depression who are undergoing Ketamine therapy, which would be a huge breakthrough for the industry. This statistical analytical approach will assist in substantiating the patient's subjective reporting experience and may allow adjustment of treatment dosage."
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. is a healthcare holding company focused on cutting edge mRNA genomic technology, therapeutics and nutraceuticals. Through its subsidiary Precision Genomics it has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and deep machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and potentially prevent chronic illnesses such as diabetes, COPD, heart disease and cancer. NuGenea™, a scientifically formulated nutraceutical, supported by decades of independent research into the anti-inflammatory properties of its compounds, is manufactured by the Ludwig subsidiary mRNAforLife, Inc and it's My RNA for Life™ product line of nutraceuticals.
Advancements in medical technology have awarded us with cutting-edge genomic tools, unheard of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genomic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including, but not limited to heart disease, diabetes, preeclampsia and cancer. This early detection may allow doctors to take steps to diagnose and manage illness before it progresses and causes serious health problems. Ludwig's innovative testing approach is not only practical but also has the potential to save the healthcare industry millions of dollars in costs. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig and its subsidiary Precision Genomics is poised to significantly impact how we think about disease and live longer healthier lives. For more information please visit: http://www.ludwigent.com.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Precision Genomics & Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises, Inc.
Anne Blackstone, CEO
786-235-9026
www.ludwigent.com
SOURCE: Ludwig Enterprises, Inc.
View source version on accesswire.com:
https://www.accesswire.com/742439/Ludwig-Enterprises-Develops-Program-to-Support-Ketamine-Clinics
Come on Recaf let's start really start moving. Wakanda forever.
What's up y'all we going up.
Metformin may reduce ageing.
Nice I think LUDG is a good stock ,,, Let's go NASQ
carusso and atlanda ASTI.
Go LUDG.
Wrong
Wrong
True.
sorry but you're wrong, it was Waller and Ramm.
He is a co/founder.
Still in Jersey.
Is there oil in this hole or what?
Anybody heard anything on Recaf
They may be trying to get OCTQB but they can say something. Right
Been quite around here.
When was the meeting.
Fck New to the st and newsmax
News!!!
Strike what?
Let's go ludg
I agree with you it's a great stock low share count, Go LUDG.
lol
I think so Drift.
Go Boy Go!
This company is a for the people company, I really like them.
Safely Test Health and Wellness Experiences with HIPAA-Compliant Feedback
December 13 2022 - 09:00AM
Business Wire
Alert
Print
Share On Facebook
New test templates unlock the patient perspective helping organizations improve the design and development of health and wellness experiences with greater ease and speed
UserTesting (NYSE: USER), a leader in video-based human insight, today announced the availability of new test templates for the UserTesting® Human Insight Platform that help companies test health and wellness experiences in the wellness applications industry, pharmaceutical industry, and medical care facilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221213005278/en/
As digital becomes a more widely used channel for customer interactions in the health and wellness industries, organizations need efficient strategies to gather customer feedback quickly, securely, and within compliance standards. UserTesting is HIPAA compliant, and the templates help companies securely gather valuable insights while adhering to regulations and requirements for data management of private health information. With human insights gathered from individuals who have opted-in to share their perspectives, organizations can quickly get real-world, real-time feedback to inform their design and development of health and wellness experiences.
Digital applications are flooding the healthcare and wellness industries. According to research, in 2021, there were more than 350,000 digital health apps available to consumers. However, only the top 110 health and wellness apps accounted for more than 50 percent downloads, while 83 percent of apps only accounted for less than 1 percent of downloads.
Further, the ONC 21st Century Cures Act Final Rule states that all Certified Health IT Developers must conduct real world testing. With access to the UserTesting Contributor Network, all companies that plan to build Certified Health IT can easily meet the requirements of demonstrating interoperability and functionality in real world settings and scenarios through the UserTesting Human Insight Platform.
To ensure a viable future and to drive continued growth, organizations need to provide customers with the best possible experiences across all channels. The UserTesting templates for healthcare and wellness experiences incorporate best practices for recruiting contributors, securing consent to discuss health-related topics, and gathering feedback within the bounds of HIPAA regulations.
This UserTesting template bundle is designed to provide health and wellness organizations with evaluations of patient portals, electronic health records and health and wellness apps; wearable device testing of fitness trackers, monitoring devices, and more; gathering patient experience feedback on in-person, telehealth, or long-term care experiences; and guidance on best practices for healthcare messaging comprehension.
Organizations can use UserTesting’s pre-built questions as-is or customize the templates to address their specific needs. Capturing feedback can be done by leveraging the UserTesting first-party, opt-in network of contributors or getting feedback directly from their own network of customers, partners, and employees.
“The emergence of promising technology for the health and wellness industries is significantly driving growth in this market. During digital transformation, it is paramount that organizations reflect on how new developments of digital apps or wearable devices are impacting their end users,” said Janelle Estes, Chief Insights Officer of UserTesting. “Having the human insight to help guide the design, development, and deployment of apps, devices, and patient interactions, while meeting regulatory standards, brings confidence and assurance to health and wellness organizations looking to uplevel their customer experiences.”
The new templates are focused on helping companies to test healthcare and wellness experiences and add to the more than 100 pre-built testing templates available on the UserTesting Human Insight Platform.
About UserTesting
UserTesting (NYSE: USER) has fundamentally changed the way organizations get insights from customers with fast, opt-in feedback and experience capture technology. The UserTesting Human Insight Platform taps into our global network of real people and generates video-based recorded experiences, so anyone in an organization can directly ask questions, hear what users say, see what they mean, and understand what it’s actually like to be a customer. Unlike approaches that track user behavior then try to infer what that behavior means, UserTesting reduces guesswork and brings customer experience data to life with human insight. UserTesting has more than 2,500 customers, including more than half of the world’s top 100 most valuable brands according to Forbes. UserTesting is headquartered in San Francisco, California. To learn more, visit www.usertesting.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005278/en/
UserTesting, Inc.
Andy Dear
press@usertesting.com
What's going on with RECAF.
She is going to blow soon ,better not wait.
It going up fast .50 in the horizon.
What the hell is happening to Recaf, are you kidding me.
It's getting HOT in here
This will blow big time soon.
Keep going up you bad boy, Go Ludg,
Their a bunch of talking fools.
Come on ludg lets go go go.
Why aren't you moving Ludwig.